NCT03153462Approved For Marketing不适用
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma.
适应症
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 15
研究概览
简要总结
A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma.
Subjects who received an infusion of axicabtagene ciloleucel will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed large B-cell lymphoma, including the following types:
- •DLBCL, not otherwise specified
- •Primary mediastinal large B-cell lymphoma
- •High-grade B-cell lymphoma
- •DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL)
- •Relapsed or refractory disease, defined as one or more of the following:
- •No response to first-line therapy (primary refractory disease); subjects who are intolerant to first-line therapy chemotherapy are excluded OR
- •No response or relapse to second or greater lines of therapy OR
- •Relapsed after ASCT
- •Subjects must have received adequate prior therapy including at a minimum:
- •anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 negative, and
- •an anthracycline containing chemotherapy regimen;
- •No evidence, suspicion, and/or history of central nervous system (CNS) involvement of lymphoma
- •Age 18 or older
- •Eastern cooperative oncology group (ECOG) performance status of 0 or 1
- •Absolute neutrophil count ANC ≥1000/μL
- •Platelet count ≥75,000/μL
- •Absolute lymphocyte count ≥100/μL
- •Adequate renal, hepatic, pulmonary and cardiac function defined as:
- •Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min
- •Serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤2.5 upper limit of normal (ULN)
- •Total bilirubin ≤1.5 mg/dL, except in subjects with Gilbert's syndrome.
- •Cardiac ejection fraction ≥ 50% and no evidence of pericardial effusion within 180 days provide the subject did not receive an anthracycline based treatment or experience a cardiac event or change in performance status
- •No clinically significant pleural effusion
- •Baseline oxygen saturation >92% on room air
- •Cohort 2 inclusion criteria: Subjects whose commercial manufacture of axicabtagene ciloleucel did not meet commercial release specification(s)
排除标准
- •History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years
- •History of allogeneic stem cell transplantation (SCT)
- •Prior CD19 targeted therapy
- •Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy
- •History of severe, immediate hypersensitivity reaction attributed to aminoglycosides
- •Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous (IV) antimicrobials for management. Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the Kite Pharma Medical Monitor
- •History of human immunodeficiency virus (HIV) infection or acute or chronic active hepatitis B or hepatitis C infection. Subjects with a history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines
- •History or presence of primary CNS lymphoma and/or CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement
- •Cohort 2 exclusion criteria: Any medical condition that, deemed by the investigator, may interfere with assessment of safety or efficacy of study treatment
研究者
研究点 (15)
Loading locations...
相似试验
终止
3 期
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)Depressive Disorder, MajorNCT03668600Naurex, Inc, an affiliate of Allergan plc230
已完成
3 期
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.Polycythemia VeraNCT02292446Novartis Pharmaceuticals161
已完成
2 期
A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer StudySolid CancersNCT00096941Genentech, Inc.3
已完成
4 期
SUBLOCADE Rapid Initiation Extension StudyOpioid Use Disorder, SevereOpioid Use Disorder, ModerateNCT04060654Indivior Inc.17
已完成
3 期
An open-label, multicenter, randomized, controlled adaptive study to evaluate the efficacy and safety of investigational therapeutics for the treatment of hospitalized patients with mild to moderate novel coronavirus disease (COVID-19) in Kinshasa, Democratic Republic of the CongoISRCTN16254682Creppat Laboratories SAR376